Vivus maintained at outperform by RBC

RBC Capital Markets analyst Ken Trbovich kept Vivus Inc. at outperform, speculative risk with a $6 price target on news of the company's better-than-expected second-quarter results. Revenue of $2.6 million beat the analyst's estimated $700,000. Total operating expenses were in line with expectations and the company reported a loss of $0.17 per share, compared to RBC's estimate of a loss of $0.12 per share. Shares of the Mountain View, Calif.-based biopharmaceutical company were down 1 cent, or 0.32%, at $3.15 on volume of 161,042 shares versus the three-month running average of 542,177 shares. (Nasdaq: VVUS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.